Experience

GeneTether Therapeutics Inc. completes C$4.5 million initial public offering

Reading Time 1 minute read
Share

Overview

On March 29, 2022, GeneTether Therapeutics Inc. (CSE: GTTX) ("GeneTether" or the "Company"), an innovative genetic medicines company, completed an initial public offering (the "IPO") of units of the Company and a concurrent non-brokered private placement (together with the IPO, the "Public Offering"). Pursuant to the Public Offering, the Company issued 7,500,000 units at a price of C$0.60 per unit for aggregate gross proceeds of C$4,500,000. Research Capital Corporation acted as the sole agent and bookrunner for the IPO.

Fasken advised Research Capital Corporation with a team led by John Sabetti and including Onyi Ubah, Taylor West (Corporate Finance & Securities), Mitchell Thaw (Tax) and Armand Benitah (Intellectual Property).

 

Jurisdiction

  • Ontario

Team

  • John M. Sabetti, Partner | Mergers & Acquisitions, Toronto, ON, +1 416 865 4455, [email protected]
  • Onyi Ubah, Associate | Corporate/Commercial, Toronto, ON, +1 416 943 8892, [email protected]
  • Armand M. Benitah, Partner | Patent Agent | Trademark Agent | Trademarks Law, Toronto, ON, +1 416 868 3470, [email protected]
John Sabetti Toronto Lawyer John M. Sabetti Partner | Mergers & Acquisitions Toronto, ON +1 416 865 4455
Onyi Ubah Toronto Lawyer Onyi Ubah Associate | Corporate/Commercial Toronto, ON +1 416 943 8892
Armand M Benitah Toronto Lawyer Armand M. Benitah Partner | Patent Agent | Trademark Agent | Trademarks Law Toronto, ON +1 416 868 3470
+1 418 640 2050